Alkaline Phosphatase: Longevity-Medicine Target Ranges for Women

What Alkaline Phosphatase Actually Measures (and Why One Number Is Never Enough)

ALP is a family of enzymes, not a single molecule. Four main tissue sources produce ALP that ends up in your blood: liver, bone, placenta, and intestine. Your standard lab report adds them all together and gives you one number. That single number tells you almost nothing without context about which tissue is the source, and for women, the source shifts dramatically across your lifespan.

A 2020 analysis published in JAMA Network Open confirmed that ALP values vary significantly by sex, age, and physiologic state, and that sex-specific reference intervals improve clinical interpretation. Most commercial labs still use wide unisex or minimally age-stratified ranges. That gap is exactly what longevity medicine is trying to close.

The Four ALP Isoenzymes You Should Know

Liver ALP (LALP) rises when bile flow is obstructed or liver cells are stressed. It is the isoenzyme most clinicians think of first and the one most associated with fatty liver disease, gallstones, and medication hepatotoxicity.

Bone ALP (BALP) reflects osteoblast activity. High BALP means bone is being built or remodeled actively. It rises in growing adolescents, after fractures, in Paget disease, and in hyperparathyroidism. It also rises in postmenopausal women as estrogen loss removes its brake on bone turnover.

Placental ALP (PALP) is the reason pregnancy produces some of the highest ALP readings a woman will ever see outside of disease. PALP is synthesized by the syncytiotrophoblast and pours into maternal circulation from the second trimester onward. By 36 weeks, total ALP is commonly 2 to 4 times a woman's pre-pregnancy baseline, and values up to 400 U/L can be entirely normal.

Intestinal ALP (IALP) is a minor contributor in most people, though it rises after fatty meals, particularly in blood type O and B individuals who are secretors.

When to Fractionate

If your total ALP is elevated and your clinician cannot tell from context whether it is bone or liver, the next step is fractionation. GGT (gamma-glutamyl transferase) is the most practical first move: GGT rises with liver injury but stays normal when elevated ALP comes from bone. A full ALP isoenzyme panel (sent to a reference lab) gives precise percentages of each fraction when the clinical picture remains unclear.

Standard Lab Ranges vs. Longevity-Medicine Targets: What the Research Shows

The standard reference interval on most US lab reports is approximately 35-150 U/L for adult women. That range was built to flag disease in general clinical populations, not to identify the metabolic sweet spot associated with the longest healthspan. Longevity medicine asks a sharper question: within the "normal" band, which ALP values predict the best long-term outcomes?

The Evidence for a Tighter Target

A large prospective cohort, the NHANES-linked mortality analysis by Rubin et al., found that ALP levels above 90 U/L in non-pregnant adults were independently associated with higher all-cause and cardiovascular mortality, even when values fell within the conventional normal range. The association was graded, not binary: risk crept up progressively above 90 U/L rather than switching on at 150 U/L.

A 2021 systematic review in the BMJ of biomarker-based longevity panels noted ALP as one of a small set of inexpensive, widely available markers whose upper-normal elevation reliably predicts accelerated biological aging across multiple organ systems.

Based on these data, the WomanRx clinical framework uses the following ALP targets for non-pregnant women:

| Life Stage | Longevity Target (U/L) | Notes | |---|---|---| | Reproductive years (18-45) | 40-80 | Confirm no recent fracture or high-impact exercise before investigating | | Perimenopause (45-55) | 45-90 | Bone turnover accelerates; trend over time matters more than one value | | Postmenopause (>55, no HRT) | 50-95 | Higher threshold reflects expected bone remodeling increase | | Postmenopause on estrogen HRT | 40-85 | Estrogen partially suppresses bone ALP; similar to reproductive-years target | | Pregnancy (any trimester) | Not applicable; use trimester-specific placental-adjusted norms | See pregnancy section below | | Adolescence (active growth) | 100-300+ physiologically normal; do not apply adult targets | |

These are working clinical targets, not FDA-cleared diagnostic cutoffs. They reflect current longevity-medicine consensus and should be interpreted alongside GGT, ALT, AST, bone turnover markers (P1NP, CTX), and parathyroid hormone.

Low ALP: The Under-Discussed Half of the Range

Most clinical conversations focus on high ALP, but values below 30-35 U/L deserve equal attention. Persistently low ALP may indicate hypophosphatasia (HPP), a genetic disorder of bone mineralization caused by ALPL gene mutations. HPP has a female-predominance in its milder adult-onset forms, presenting as stress fractures, tooth loss, joint pain, and fatigue, symptoms that are frequently misattributed to osteoporosis, fibromyalgia, or perimenopause.

If your ALP runs below 30 U/L on two separate draws and you have any of those symptoms, ask for a serum pyridoxal-5-phosphate (PLP) level and refer to a metabolic bone specialist.

How Hormones and the Menstrual Cycle Change Your ALP

This is where women's physiology diverges sharply from what most general lab guides describe. ALP is not a static number between your annual blood draws.

Cycle-Phase Variation

ALP shows modest but real variation across the menstrual cycle. A study in Clinical Chemistry documented a small mid-cycle peak in bone ALP coinciding with the LH surge, likely reflecting the transient anabolic effects of the pre-ovulatory estradiol spike. The variation is generally within 10-15 U/L and rarely changes clinical interpretation, but it explains why two draws taken two weeks apart in the same woman can look meaningfully different.

For longevity tracking purposes, standardize your ALP draw to the early follicular phase (days 2-5 of your cycle) whenever possible, so you are comparing like with like across years.

Perimenopause: Bone Turnover Accelerates

Estrogen suppresses osteoclast activity. As estrogen becomes erratic in perimenopause, bone resorption outpaces bone formation, and both BALP and the resorption marker CTX rise. The Study of Women's Health Across the Nation (SWAN) documented an approximate 15-20% increase in bone turnover markers during the menopausal transition, and total ALP reflects part of that shift.

An ALP of 95 U/L in a 50-year-old perimenopausal woman whose GGT is normal and whose BALP fraction accounts for most of the total is very different from an ALP of 95 U/L in the same woman with elevated GGT and a history of alcohol use. The number alone is not the story.

Postmenopause and the Role of HRT

Postmenopausal women not using hormone replacement therapy (HRT) show consistently higher bone ALP than premenopausal women, consistent with the loss of estrogen's restraint on bone remodeling. Estrogen therapy, whether oral or transdermal, partially normalizes bone turnover. The WHI Bone Density Substudy confirmed that conjugated equine estrogen 0.625 mg/day reduced bone-specific ALP by approximately 20% compared to placebo over three years.

If you are on HRT and your ALP trends upward despite that treatment, that trajectory warrants investigation for secondary causes: vitamin D deficiency, primary hyperparathyroidism (more common in postmenopausal women), or Paget disease.

Pregnancy and Lactation: ALP Interpretation Is Entirely Different

This section replaces standard ALP norms for any pregnant or recently postpartum reader. Standard lab reference ranges do not apply during pregnancy, and flagging a pregnant woman's ALP as "elevated" using non-pregnant norms is a common and consequential clinical error.

ALP in Pregnancy by Trimester

ALP rises progressively through pregnancy, driven almost entirely by PALP from the placenta. By the third trimester, total ALP commonly reaches 2-4 times the non-pregnant baseline, and values of 200-400 U/L may be completely normal. The liver and bone fractions contribute modestly on top of that placental surge.

Trimester-specific reference intervals from the NICHD Fetal Growth Study provide the most granular pregnancy norms currently available. Your obstetric provider should use those gestational-age-specific ranges, not general adult ranges, when reviewing your ALP.

When High ALP in Pregnancy Is a Warning Sign

A key exception is intrahepatic cholestasis of pregnancy (ICP). ICP affects approximately 0.5-2% of pregnancies and is characterized by intense pruritus, elevated bile acids, and a pattern of liver enzyme elevation that includes ALP rising above what the placental contribution alone would predict. GGT and bile acids become critical in this scenario. If you have persistent itching, particularly on your palms and soles at night, and your ALP or bile acids are elevated, contact your obstetric provider the same day.

Postpartum and Lactation

PALP clears from circulation within two to four weeks postpartum as the placenta is delivered. ALP normalizes to pre-pregnancy values within four to six weeks in most women. Lactation itself does not substantially alter total ALP, though bone resorption does increase during exclusive breastfeeding, meaning bone ALP may remain mildly elevated for several months postpartum. This is physiologic and resolves with weaning.

ALP testing carries no specific risks during pregnancy or lactation. It is a blood draw, not a drug. No contraception requirements apply.

Conditions That Push ALP Up or Down in Women: A Targeted List

Women carry a disproportionate burden of several conditions that directly alter ALP. Knowing which conditions are on the list helps you understand your own result.

Conditions That Raise ALP

Primary biliary cholangitis (PBC) is 90% female and its hallmark lab finding is a cholestatic pattern of ALP elevation, often 3-10 times the upper limit of normal, with relatively preserved ALT and AST. PBC-specific ALP targets post-treatment (with ursodeoxycholic acid or obeticholic acid) now drive management decisions in current AASLD guidelines.

Primary hyperparathyroidism (PHPT) is two to three times more common in postmenopausal women than in men of similar age. PHPT raises bone ALP through increased osteoclast-driven bone turnover and is frequently diagnosed incidentally on routine labs.

Celiac disease, more prevalent in women, can raise ALP through both a liver pattern (celiac hepatitis) and a bone pattern (secondary hyperparathyroidism from malabsorption-driven vitamin D deficiency).

Thyroid disease, specifically untreated hyperthyroidism, accelerates bone turnover and raises bone ALP. Women with subclinical hyperthyroidism (TSH <0.1 mU/L) show measurably higher BALP than euthyroid controls.

Non-alcoholic fatty liver disease (NAFLD/MASLD) in women often presents differently than in men: postmenopausal women with NAFLD may show a predominantly cholestatic ALP pattern rather than the transaminase-dominant pattern more common in men.

Conditions and Drugs That Lower ALP

Hypothyroidism suppresses bone turnover and can bring ALP to the low end of normal or below. This is relevant for women with Hashimoto thyroiditis.

Zinc deficiency impairs ALP activity directly; ALP requires zinc as a cofactor. Women following restrictive diets, vegetarians, and those with inflammatory bowel disease may show low ALP partly on this basis.

Certain medications lower ALP: high-dose estrogen, clofibrate, and cardiac glycosides can all suppress ALP activity. If you are on any of these, your low ALP result needs context.

How to Track ALP Longitudinally: A Practical Protocol for Women

A single ALP value is a photograph. A series of values over time is a film, and the film is what longevity medicine actually uses.

Recommended Testing Frequency

For women with no known liver or bone disease, a baseline ALP fractionated into isoenzymes (or paired with GGT, ALT, AST, PTH, 25-OH vitamin D, P1NP, and CTX) provides a comprehensive metabolic snapshot. After that baseline, annual retesting of total ALP alongside your other metabolic markers is sufficient for most women in their reproductive years.

In perimenopause and postmenopause, consider twice-yearly ALP as part of a bone turnover panel, particularly in the first two years after the final menstrual period, when bone loss is fastest. Bone loss in the first one to three years of menopause averages 2-4% per year at the spine, and tracking bone ALP trends gives you an early signal before DXA changes become visible.

Interpreting Trends Over Time

A rise of more than 20% from your personal baseline over 12 months, without an obvious physiologic explanation (fracture, pregnancy, adolescent growth), warrants investigation even if the new value sits within the conventional normal range.

A fall from a previously stable value to below 35 U/L, especially if accompanied by any musculoskeletal symptoms, should prompt evaluation for hypophosphatasia before attributing the change to medication effect or diet.

Who Should Pay the Most Attention to Their ALP Result

Not every woman needs to scrutinize her ALP with equal intensity. These are the women for whom ALP carries the most clinical signal:

Postmenopausal women not on HRT. Bone ALP trends predict fracture risk trajectories over and above DEXA alone in some analyses. A BALP above the premenopausal reference range in a postmenopausal woman is associated with a roughly 2-fold increase in hip fracture risk.

Women with known or suspected PBC, celiac disease, or PHPT. ALP is a treatment-response marker in all three conditions, not just a screening value.

Women on long-term medications known to affect ALP. Anti-epileptic drugs (phenytoin, carbamazepine), proton pump inhibitors, and glucocorticoids all shift ALP, usually upward via bone isoenzyme induction.

Women pursuing longevity medicine protocols. If you are tracking biological age markers, ALP belongs in your panel. Values persistently in the upper quartile of "normal" (100-149 U/L) are associated with measurably worse metabolic aging scores in phenotypic age analyses based on Levine et al..

Women with unexplained fatigue, stress fractures, or premature tooth loss at any age. These symptoms alongside a low ALP are the HPP triad and deserve specialist evaluation.

The Evidence Gap: What We Still Do Not Know

Women have been under-represented in the clinical trials and epidemiologic cohorts used to set ALP reference intervals. Most foundational reference-range studies were conducted in populations that did not stratify by menstrual cycle phase, hormonal contraceptive use, HRT type or dose, or specific life stage beyond broad age buckets.

The longevity-medicine target of 40-90 U/L for non-pregnant women is supported by mortality data (primarily from NHANES-linked cohorts) and mechanistic reasoning about bone and liver biology, but it has not been validated in a prospective randomized trial with women-specific endpoints. What we know is extrapolated from mixed-sex cohorts and observational data.

Sex-specific isoenzyme reference intervals across the reproductive lifespan remain an active area of research. Until those data exist, interpreting ALP in the context of your full hormone panel, your specific life stage, and your GGT is the most clinically sound approach available.